Medicinal Products

833. Deputy Cian O'Callaghan asked the Minister for Health if she will ensure that a new medication (details supplied) is processed on the HSE reimbursement list as quickly as possible when it is given EU approval; if she will take action to make this medication available for all children with Duchenne Muscular Dystrophy; and if she will make a statement on the matter. [32302/25]

858. Deputy Barry Ward asked the Minister for Health if her attention has been drawn to the concerns of pharmacists regarding the prohibitive cost of the shingles vaccine, despite it being recommended by the National Immunisation Advisory Committee; if her Department has engaged with the manufacturer in any way to seek a reduction in price per unit; and if she will make a statement on the matter. …

861. Deputy Ged Nash asked the Minister for Health if she is aware of the issues Duchenne muscular dystrophy patients are having getting timey access to a new drug for the condition (details supplied); if immediate steps will be taken to make this drug available; and if she will make a statement on the matter. [32396/25]

870. Deputy Cormac Devlin asked the Minister for Health the status of consideration, use (even on a trial basis), and funding for the drug givinostat for Duchenne muscular dystrophy; and if she will make a statement on the matter. [32461/25]

882. Deputy Paul Donnelly asked the Minister for Health if there are plans to further roll out the free HRT scheme to men and others who use HRT for medical reasons. [32518/25]

885. Deputy Liam Quaide asked the Minister for Health her plans to make eylea or aflibercept, available to suitable patients in Irish hospitals for the treatment of the wet form of age-related macular degeneration; and if she will make a statement on the matter. [32555/25]

923. Deputy Darren O'Rourke asked the Minister for Health if she is considering an early access programme to givinostat (details supplied) for Duchenne muscular dystrophy patients in Ireland, similar to that provided in Scotland; and if she will make a statement on the matter. [32733/25]

924. Deputy Darren O'Rourke asked the Minister for Health if she is considering providing access to fivinostat for non-ambulant Duchenne muscular dystrophy patients in Ireland in addition to ambulant patients; and if she will make a statement on the matter. [32734/25]

931. Deputy Pádraig Rice asked the Minister for Health the steps she will take to ensure that adults with spinal muscular atrophy receive access to approved medicines (details supplied); if she will engage in dialogue with stakeholders regarding the current age-based exclusion; and if she will make a statement on the matter. [32774/25]

939. Deputy Eoghan Kenny asked the Minister for Health if she has given consideration to a fast-tracked review of vyloy for inclusion in the HSE reimbursement scheme; and if she will make a statement on the matter. [32811/25]

940. Deputy Ryan O'Meara asked the Minister for Health if the drug, victoza, also known as liraglutide, is available under the drugs payment scheme (DPS) for patients who have had it prescribed for weight loss; if not, whether there are alternatives available under the DPS that a patient may instead discuss with their GP; and if she will make a statement on the matter. [32817/25]

502. Deputy Mairéad Farrell asked the Minister for Health if the approval of a drug will be expedited considering its urgent need by a person (details supplied). [31405/25]

534. Deputy Conor Sheehan asked the Minister for Health if she will examine and expedite the approval of a new drug givinostat which has been approved in the UK and US for the treatment of Duchenne muscular dystrophy; and if she will make a statement on the matter. [31509/25]

542. Deputy Liam Quaide asked the Minister for Health her plans to expedite the national assessment and decision process for the use of duvyzat (givinostat) to treat patients with Duchenne muscular dystrophy; and if she will make a statement on the matter. [31557/25]

1352. Deputy Albert Dolan asked the Minister for Health the rationale for excluding evorel 100mcg patches from the new hormone replacement therapy (HRT) scheme, given its widespread use as a substitute for estradot, which has been in long-term short supply; the measures being taken to ensure continuity of HRT care for those impacted by the supply shortages of estradot, including the potential incl…

1380. Deputy Louis O'Hara asked the Minister for Health the reason evorel patches, which are being dispensed in place of estradot due to an ongoing shortage, are not covered under the new free hormone replacement therapy scheme; and if she will make a statement on the matter. [29459/25]

1381. Deputy Louis O'Hara asked the Minister for Health the steps being taken to ensure hormone replacement therapy (HRT) medicine alternatives such as evorel are included in the free HRT scheme, especially given the possible long-term unavailability of estradot; if her Department or the HSE plans to reassess the coverage of such alternative HRT medication under the free HRT scheme to ensure conti…

1450. Deputy David Cullinane asked the Minister for Health if she is aware of a shortage of a skin cancer drug efudix through pharmacies; the action being taken by her Department in relation to same; and if she will make a statement on the matter. [29703/25]

1467. Deputy Colm Burke asked the Minister for Health if she is concerned by the latest data from the EFPIA Patient Wait Indicator 2024, indicating an average wait time of 645 days for access to new medicines in Ireland, which constitutes a further disimprovement on last year's figures; to outline what plans are underway to improve the structures and speed of the system, in line with the Programme…

1468. Deputy Colm Burke asked the Minister for Health if the 34 new whole-time equivalent positions for the agencies involved in the HSE's medicines pricing and reimbursement system, as initially prescribed in February 2023 by the then-Minister for Health, have now been successfully filled; whether they have commenced their engagement; and if she will make a statement on the matter. [29792/25]

1470. Deputy Colm Burke asked the Minister for Health her views on the findings of a report (details supplied) in relation to the development of a system of transferable exclusivity vouchers; whether she is supportive of the introduction of such a system at Irish and EU level; and if she will make a statement on the matter. [29794/25]

1479. Deputy Shane Moynihan asked the Minister for Health to outline the availability of estradot in Ireland, and if an alternative to this drug can be funded as part of the free HRT programme. [29831/25]

1481. Deputy Pádraig Rice asked the Minister for Health the reason for the delay in commencing the inquiry into the historical licensing and use of sodium valproate; the work carried out to date; the timeline for formal commencement; and if she will make a statement on the matter. [29835/25]

1511. Deputy Pádraig Rice asked the Minister for Health the number of patients receiving biologics medicines for severe asthma in 2024 and to date in 2025; and the specific biologic medicines included, in tabular form. [29978/25]

1512. Deputy Pádraig Rice asked the Minister for Health the number of patients receiving biologic medicines for severe asthma in 2024 and to date in 2025, by health region and hospital, in tabular form. [29979/25]